Morgan Stanley Liminal Bio Sciences Inc. Transaction History

Morgan Stanley

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.4 - $0.59 $5,542 - $8,175	-13,857 Reduced 99.56%	61 $0
Q1 2022 May 13, 2022	SELL	$0.82 - $1.13 $36,436 - $50,211	-44,435 Reduced 76.15%	13,918 $14,000
Q4 2021 Feb 14, 2022	BUY	$0.92 - $2.2 $33,775 - $80,766	36,712 Added 169.64%	58,353 $63,000
Q3 2021 Nov 15, 2021	BUY	$2.15 - $3.92 $46,528 - $84,832	21,641 New	21,641 $50,000

234

Ticker LMNL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,042,600
Description
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the trea...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.